Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group

Leukemia

Volumn 10, Issue 11, 1996, Pages 1677-1686

  Creutzig, U ^a,f   Ritter, J ^a   Vormoor, J ^a   Ludwig, W D ^b   Niemeyer, C ^c   Reinisch, I ^d   Stollmann Gibbels, B ^e   Zimmermann, M ^a   Harbott, J ^d  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL GIESSEN   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f Padiatrische Hamatologie/Onkologie   (Germany)

Author keywords

AML; Down's syndrome; FAB M7

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DOWN SYNDROME; ERYTHROCYTE; HUMAN; LEUKEMIA REMISSION; LYMPHOID CELL; MAJOR CLINICAL STUDY; MEGAKARYOBLAST; MYELODYSPLASIA; PARTIAL TRISOMY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0029838764     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Huang M-J, Li C-Y, Nichols WL, Young J-H, Katzmann JA. Acute leukemia with megakaryocytic differentiation: a study of 12 cases identified immunocytochemically. Blood. 1984; 64: 427-439.
2. Windebank KP, Tefferi A, Smithson WA, Li C-Y, Solberg LA Jr, Priest JR, Elliott SC, de Alarcon PA, Weinblatt ME, Burgert EO Jr. Acute megakaryocytic leukemia (M7) in children. Mayo Clin Proc 1989; 64: 1339-1351.
3. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 1994; 18: 163-171.
4. Creutzig U, Ritter J, Vormoor J, Eschenbach C, Dickerhoff R, Burdach S, Scheel-Walter H-G, Kühl J, Schellong G. Transiente Myeloproliferation und akute myeloische Leukämie bei Säuglingen mit Morbus Down. Klin Pädiatr 1990; 202: 253-257.
5. Robison LL, Nesbit NEJ, Sather HN, Level C, Shahidi N, Kennedy A, Hammond D. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Childrens Cancer Study Group. J Pediatr 1984; 105: 235-242.
6. Kojima S, Matsuyama T, Sato T, Horibe K, Konishi S, Tsuchida M, Hayashi Y, Kigasawa H, Akiyama Y, Okamura J et al. Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction. Blood 1990; 76: 2348-2353.
7. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome: a review. Pediatr Hematol Oncol 1987; 4: 211-230.
8. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome. A review. Pediatr Hematol Oncol 1992; 9: 139 (Abstr.).
9. bennett jm, catovsky d, daniel mT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 626-629.
10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 460-462.
11. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Ritchey AK et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992; 80: 2210-2214.
12. Creutzig U, Sperling C, Harbott J, Ritter J, Zimmermann M, Löffler H, Riehm HJ, Schellong G, Ludwig W-D. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of Study AML-BFM-87. Blood 1995; 86: 3097-3108.
13. Creutzig U, Ritter J, Zimmermann M, Schellong G, for the AML-BFM Study Group. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia (AML): unexpected results of the childhood AML Study BFM-87. J Clin Oncol 1993; 11: 279-286.
14. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
15. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1985; 53: 457-481.
16. Peto R, Pike MC. Conservatism of the approximation (O-E)x/E in the logrank test for survival data or tumor incidence data. Biometrics 1973; 29: 579-584.
17. Rosner F, Lee SL. Down's syndrome and acute leukemia: myeloblastic or lymphoblastic? Report of forty-three cases and review of the literature. Am J Med 1972; 53: 203-218.
18. Creutzig U, Ritter J, Ludwig W-D, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J. Akute myeloische Leukämie bei Kindern mit Down-Syndrom. Klin Pädiatr 1995; 207: 136-144.
19. Yumura-Yagi K, Hara J, Jurahashi H, Nishiura T, Kaneyama Y, Osugi Y, Sakata N, Inoue M, Tawa A, Okada S, Kawa-Ha K. Mixed phenotype of blasts in acute megakaryocytic leukemia and transient abnormal myelopoiesis in Down's syndrome. Br J Haematol 1992; 81: 520-525.
20. Drexler HG, Thiel E, Ludwig WD. Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance. Leukemia 1993; 7: 489-498.
21. Chabannon C, Wood P, Torok Storb B. Expression of CD7 on normal human myeloid progenitors. J Immunol 1992; 149: 2110-2113.
22. Kita K, Miwa H, Nakase K, Kawakami K, Kobayashi T, Shirakawa S, Tanaka I, Ohta C, Tsutani H, Oguma S, Kyo T, Dohy Y, Kamada N, Nasu K, Uchino H, (The Japan Cooperative Group of Leukemia/Lymphoma). Clinical importance of CD7 expression in acute myelocytic leukemia. Blood 1993; 81: 2399-2405.
23. Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, Cox C, Dallapiccola B, Papa G. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-MO). Blood 1994; 83: 1619-1625.
24. Heim S, Mitelman F. Cytogenetic analysis in the diagnosis of acute leukemia. Cancer 1992; 70: 1701-1709.
25. Lu GH, Altman AJ, Benn PA. Review of the cytogenetic changes in acute megakaryoblastic leukemia - one disease or several. Cancer Genet Cytogenet 1993; 67: 81-89.
26. Hecht F, Hecht BK, Morgan R, Sandberg AA, Link MP. Chromosome clues to acute leukemia in Down's syndrome. Cancer Genet Cytogenet 1986; 21: 93-98.
27. Kaneko Y, Rowley JD, Variakojis D, Chilcote RR, Moohr JW, Patel D. Chromosome abnormalities in Down's syndrome patients with acute leukemia. Blood 1981; 58: 459-466.
28. Fonatsch C, Haase D, Freund M, Bartels H, Tesch H. Partial trisomy 1q. A nonrandom primary chromosomal abnormality in myelodysplastic syndromes? Cancer Genet Cytogenet 1991; 56: 243-253.
29. de Alarcon PA, Patil S, Golberg J, Allen JB, Shaw S. Infants with Down's syndrome. Use of cytogenetic studies and in vitro colony assay for granulocyte progenitor to distinguish acute nonlymphocytic leukemia from a transient myeloproliferative disorder. Cancer 1987; 60: 987-993.
30. Litz CE, Davies S, Brunning RD, Kueck B, Parkin JL, Gail Peczalska KJ, Arthur DC. Acute leukemia and the transient myeloproliferative disorder associated with Down syndrome: morphologic, immunophenotypic and cytogenetic manifestations. Leukemia 1995; 9: 1432-1439.
31. Carroll A, Civin C, Schneider N, Dahl G, Pappo A, Bowman P, Emami A, Gross S, Alvarado C, Phillips C, Krischer J, Crist WM, Head D, Gresik M, Ravindranath Y, Weinstein H. The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: A Pediatric Oncology Group study. Blood 1991; 78: 748-752.
32. Lion T, Haas OA, Harbott J, Bannier E, Ritterbach J, Jankovic M, Fink FM, Stojimirovic A, Hermann J, Riehm HJ, Lampert F, Ritter J, Koch H, Gadner H. The translocation t(1;22) (p13;q13) is a non-random marker specifically associated with acute megakaryocytic leukemia in young children. Blood 1992; 79: 3325-3330.
33. Akahoshi M, Oshimi K, Mizoguchi H, Okada M, Enomoto Y, Watanabe Y. Myeloproliferative disorders terminating in acute megakaryoblastic leukemia with chromosome 3q26 abnormality. Cancer 1987; 60; 2654-2661.
34. Walker H, Smith FJ, Betts DR. Cytogenetics in acute myeloid leukaemia. Blood Rev 1994; 8: 30-36.
35. Morgan R, Hecht F, Cleary ML, Sklar J, Link MP. Leukemia with Down's syndrome: translocation between 1 and 19 in acute myelomonocytic leukemia following transient cogenital myeloproliferative syndrome. Blood 1985; 66: 1466-1468.
36. Hayashi Y, Eguchi M, Sugita K, Nakazawa S, Sato T, Kojima S, Bessho F, Konishi S, Inaba T, Hanada R, Yamamoto K. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood 1988; 72: 15-23.
37. Suarez CR, Le Beau MM, Silberman S, Fresco R, Rowley JD. Acute megakaryoblastic leukemia in Down's syndrome: report of a case and review of cytogenetic findings. Med Pediatr Oncol 1985; 13: 225-231.
38. Alimena G, Billstrom R, Casalone R, Gallo E, Mitelman F, Pasquali F. Cytogenetic pattern in leukemic cells of patients with constitutional chromosome anomalies. Cancer Genet Cytogenet 1985; 16: 207-218.
39. Wang N, Leung J, Warrier RP, Schorin M, Kirkpatrick D, Nowak MJ, Strand R. Nonrandom chromosomal aberrations and clonal chromosomal evolution in acute leukemia associated with Down's syndrome. Cancer Genet Cytogenet 1987; 46: 271-280.
40. Zipursky A, Wang H, Brown EJ, Squire J. Interphase cytogenetic analysis of in vivo differentiation in the myelodysplasia of Down syndrome. Blood 1994; 84: 2278-2282.
41. Yumura-Yagi K, Hara J, Tawa A, Kawa-Ha K. Phenotypic characteristics of acute leukemia and transient megakaryocytic leukemia and transient abnormal myelopoiesis. Leuk Lymphoma 1994; 13: 393-400.
42. Taub JW, Matherly LH, Buck SA, Stout M, Ravindranath Y. Enhanced formation of cytarabine triphosphate (ara-CTP) in Down syndrome cells: possible explanation for superior disease free survival of Down syndrome children with acute myeloid leukemia. Blood 1994; 84 (Suppl. 1): 515 (Abstr.).
43. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan S, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Engl J Med 1991; 324: 808-815.